Single-agent activity of phosphatidylinositol 3-kinase inhibition with copanlisib in patients with molecularly defined relapsed or refractory diffuse large B-cell lymphoma

Patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) have adverse outcomes. We evaluated the efficacy and safety of the phosphatidylinositol 3-kinase inhibitor copanlisib in patients with relapsed/refractory DLBCL and assessed the relationship between efficacy and DLBCL cell of or...

Descripción completa

Detalles Bibliográficos
Autores principales: Lenz, Georg, Hawkes, Eliza, Verhoef, Gregor, Haioun, Corinne, Thye Lim, Soon, Seog Heo, Dae, Ardeshna, Kirit, Chong, Geoffrey, Haaber, Jacob, Shi, Wei, Gorbatchevsky, Igor, Lippert, Susanne, Hiemeyer, Florian, Piraino, Paolo, Beckmann, Georg, Peña, Carol, Buvaylo, Viktoriya, Childs, Barrett H., Salles, Gilles
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7387311/
https://www.ncbi.nlm.nih.gov/pubmed/32060403
http://dx.doi.org/10.1038/s41375-020-0743-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7387311/
https://www.ncbi.nlm.nih.gov/pubmed/32060403
http://dx.doi.org/10.1038/s41375-020-0743-y

Ejemplares similares